Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

ESMO 2019

27 Sep - 1 Oct 2019

Published: 28 Sep 2019

Views: 1180

Rating:

Save

Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA

Prof Suresh Ramalingam presents data from the FLAURA trial during a press conference at the 2019 ESMO congress.

This was a trial looking at first-line osimertinib in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer (NSCLC) compared with older generation EGFR-TKIs.

Watch Dr Pilar Garrido's comment here.

Watch Dr Marina Garassio's comment here.

Read more about the study here.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

The latest in NSCLC with common EGFR mutations

Dr Alfredo Addeo, Dr Antonio Passaro, Dr Alex Spira and Prof Amanda Tufman

The latest in NSCLC with common EGFR mutations ( Dr Alfredo Addeo, Dr Antonio Passaro, Dr Alex Spira and Prof Amanda Tufman )

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR...

Prof Nicolas Girard - Institut Curie, Paris, France

Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Four chemo cycles given with durvalumab and tremelimumab optimise response and...

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for...

Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA

CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC ( Dr David Waterhouse - Dana-Farber Cancer Institute, Boston, USA )

Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1...

Dr Margarita Majem Tarruella - Hospital de la Santa Creu i Sant Pau, Barcelona...

Final data from phase II study of eftilagimod alpha and pembro in PD-1/PD-L1 inhibitors resistant second line metastatic NSCLC ( Dr Margarita Majem Tarruella - Hospital de la Santa Creu i Sant Pau, Barcelona, Spain )

OncoAlert and ecancer weekly round up for August 8th - 14th, 2022

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for August 8th - 14th, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

ASCO Direct Highlights 2022: lung cancer highlights

Dr Tom Stinchcombe - Duke Cancer Center, Durham, USA

ASCO Direct Highlights 2022: lung cancer highlights ( Dr Tom Stinchcombe - Duke Cancer Center, Durham, USA )

More from ecancer